BioHealthonomics

Cris Arnou has been the Founder, CEO, and Director of BioHealthonomics, Inc since inception in 2011. As a migraine sufferer for more than 35 years he is determined and committed to developing the technology that addresses migraine headaches from a root cause stand point. In the past, Mr Arnou has worked for two start-up companies, Fisker Automotive and Coda Automotive, and knows what it takes to build a successful, prosperous business. Cris holds Bachelor and Master Degrees in Engineering from the University of Michigan, Ann Arbor and an MBA from Wayne State University in Detroit. He is a veteran of the U.S. Army. Cris lives in the Los Angeles area together with his wife of 25 years and their 2 kids.

Dr. Chappell is a board certified neurologist with special competence in child neurology. She retired from Lilly Research Laboratories in January 2014, after 25 years in clinical research where she most recently served as the Neuroscience Senior Medical Fellow. She designed and conducted clinical trials through all phases of development in neurological disorders including epilepsy, ALS, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, migraine and pain disorders (fibromyalgia, osteoarthritis, chronic low back pain, lumbar radiculopathy, spinal cord injury). She was the lead physician for the development of duloxetine for fibromyalgia, which resulted in an FDAapproval. Dr. Chappell continues to practice neurology, most recently as clinical associate professor at the Indiana University Medical Center. Positions over the last (3) years include: 1. Chief Medical Officer, BioHealthonomics Inc., July 2014 to present. 2. Chairman of the Board, Naples YMCA, December 2016 to present. 3. Consulting Neurology Director, Biogen/Convergence, May 2014 to present. 4. Program Facilitator - Complete Health Improvement Program, October 2014 to present. 5. Board member, American Society of Experimental Neurotherapeutics, 1998 to present. 6. Physician member, American College of Lifestyle Medicine, 2014 to present. 7. Principal Investigator, Neuroscience, Naples Research, January 2016 to March 2017. 8. Fellow, American College of Sports Medicine, 1984 to present

Randy Jones is the Chief Legal Officer, Secretary and Director for BioHealthonomics. Inc. He is also Principal of Solutions Business Group, which he founded in 2009 as a business services firm dedicated to assisting for-profit and non-profit businesses achieve stretch goals, resolve difficult challenges and navigate periods of change or transition. Prior to founding Solutions Business Group, Mr. Jones spent more than 20 years working for global corporations in a wide range of industries including pharmaceuticals, biotech, energy and chemicals. His distinguished career encompasses a variety of roles including engineer, in-house legal counsel and senior executive in charge of legal, human resources, corporate compliance and ethics. Mr. Jones also spent 6 years as General Counsel of Talecris Biotherapeutics, a company that reached a $4.4B market cap. Mr. Jones holds a Bachelor of Chemical Engineering from the University of Delaware and a Juris Doctor from the University of Virginia. Positions over the last (3) years include: 1. Founder and Principal, Solutions Business Group, 2009 to present. 2. Chief Legal Officer, Secretary and Director, BioHealthonomics Inc., May 2016 to present.

Dr. Freitag is currently on the Board of Directors of the National Headache Foundation, position he held since 1993. Dr. Freitag is also the director of the Headache Medicine program and UCNS Headache Medicine Fellowship at Froedtert Hospital and the Medical College of Wisconsin where he is an Associate Professor in the Department of Neurology. He previously held the same positions at Baylor University Medical Center in Dallas Texas where he led the development of the comprehensive headache treatment program between 2010 and 2013. For 27 years he was affiliated with the Diamond Headache Clinic and inpatient treatment program where he was co-director at the time of his leaving. He was responsible for clinical and basic science research there for 24 years. He received his bachelor of science in Biochemistry from the University of Wisconsin and his DO degree from the Chicago College of Osteopathic Medicine in 1979. He is a Fellow of the American Headache Society.

Dr. Grannatt retired September 2012 after 25 years in the global pharmaceuticals industry. He was Vice President of Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive, diversified UK-based company. Additionally, Dr. Grannatt has an extensive deal sheet experience. Dr. Grannatt currently serves as an outside Director of SymBio Pharmaceuticals Limited, a publicly-traded Japanese pharmaceutical company; a member of the advisory boards of VOX Telehealth and BioHealthonomics Inc; and an advisor to selected other biotech companies. In addition, he is a member of the Board of Governors for Certified Licensing Professionals, and is a lecturer in economics at Princeton’s Evergreen Forum. Dr. Grannatt received his undergraduate degree and PhD in economics from Lehigh University.

Stephen D. Silberstein, MD, is Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University. He is a Fellow of the American College of Physicians, the American Academy of Neurology, and the American Headache Society. He has served the American Headache Society as President, Treasurer, and Board of Directors member. He has served on the Publications, Scientific, and Education Committees of the American Headache Society and was Co-chairman of the Annual Scientific Meeting. He is Chairman of the headache research group of the World Federation of Neurology. Dr. Silberstein received his medical degree from the University of Pennsylvania. After completing a fellowship in neurology at the National Hospital for Nervous Diseases in London, Dr. Silberstein served as a Pharmacology Research Associate in the Toxicology Laboratory of Clinical Science at the National Institutes of Mental Health, and completed a neurology residency at the Hospital of the University of Pennsylvania. Dr. Silberstein is the Senior Editor of the 8th edition of Wolff’s Headache and Other Head Pain, Associate Editor of Cephalalgia and CNS Drugs, and a present or prior member of the Editorial Board of Headache; Cephalalgia; Acta Neurologica Scandinavica; Journal of Neurology, Neurosurgery & Psychiatry; and Topics in Pain Management. He is an ad hoc reviewer for many publications, including The New England Journal of Medicine; Brain, The Lancet, JAMA, Mayo Clinic Proceedings, Annals of Neurology, and Neurology. Dr. Silberstein has more than 300 publications to his credit. He lectures extensively on the pathogenesis, neurobiology, diagnosis, and treatment of headache.

Founding CEO AstraMerck Former CEO, Novartis U.S Chairman, NuPathe Inc Mr. Yetter is a retired pharmaceutical and healthcare executive and has held several Chief Executive and Board of Directors roles during his career. These roles included founding CEO of AstraMerck, Inc. (now Astra Zeneca) and CEO of Novartis Pharmaceuticals (US). He has also served as Chairman of the Board or Lead Independent Director at several public and private corporations. Positions over the last three (3) years include: 1. Chairman of the Board, NuPathe, Inc. (PATH) 2010-2014. NuPathe was acquired by TEVA Pharmaceuticals in February 2014. 2. Director, InfuSystem Holdings, Inc. (INFU) 2007-September 2016. Served as Chair of a Special Independent Board Committee to assess a take over private transaction proposed by the Board Chairman. The proposal was not supported. 3. Director, Strategic Diagnostics, Inc. (SDIX) and its post transaction “shell company”, Special Diversified Opportunities, Inc. (SDOI) 2010 – August 2017. Chaired Specail Committee to review transaction with Standard General completed during August, 2017. 4. Director, Espero Pharmaceuticals 2016 – Present. Merger with Armetheon, Inc. completed in October, 2017. Mr. Yetter serves as a Director of the merged company now named Espero BioPharma, Inc. 5. Director of the Hepatitis B Foundation (Doylestown, PA) and its associated research organization, the Baruch S. Blumberg Institute, 2014-Present. 6. Member, Healthcare Advisory Board, Safeguard Scientifics (SFE) 2010-2014. 7. Advisory Board, BioHealthonomics Inc., 2014 to present